Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

【24h】

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

机译：基于伊立替康的一线化疗在转移性结直肠癌中的药物遗传学定制：一项初步研究的结果。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND: Tolerability to irinotecan may be explained by pharmacogenomic polymorphisms. The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer. PATIENTS AND METHODS: Patients with favourable TS and UGT1A1 profiles received high-dose (HD) FOLFIRI. Patients with TS-3R/3R could not receive HD-FOLFIRI, and those with UGT1A1-7/7 received standard FOLFIRI. The endpoints were overall response rate and safety. RESULTS: Sixty-nine patients were enrolled in the study. Sixty-five patients received chemotherapy. Twenty patients (30.8%) achieved a partial response. The haematological toxicity was less in the HD-FOLFIRI subgroup. Patients having received HD-FOLFIRI did not experience increased levels of nausea-vomiting, asthenia or alopecia. Diarrhoea was more frequent with HD-FOLFIRI. CONCLUSION: The genotypic assessment allowed a safer use of HD-FOLFIRI. Further investigations may target patients who benefit from intensification.

机译：背景：对伊立替康的耐受性可以通过药物基因组多态性解释。这项药物遗传学试验的目的是研究胸苷酸合酶（TS）基因型与尿苷二磷酸葡萄糖醛糖基转移酶（UGT1A1）的同工型1A1的相关性，以量身定制5-氟尿嘧啶，亚叶酸和伊立替康（FOLFIRI）的联合化疗方案转移性结直肠癌。患者和方法：TS和UGT1A1谱良好的患者接受大剂量（HD）FOLFIRI。 TS-3R / 3R患者无法接受HD-FOLFIRI，UGT1A1-7 / 7患者则接受标准FOLFIRI。终点是总体响应率和安全性。结果：69例患者被纳入研究。 65例患者接受了化疗。 20名患者（30.8％）获得了部分缓解。 HD-FOLFIRI亚组的血液学毒性较小。接受HD-FOLFIRI的患者的恶心呕吐，乏力或脱发没有增加。 HD-FOLFIRI腹泻更为频繁。结论：通过基因型评估，可以更安全地使用HD-FOLFIRI。进一步的检查可能针对受益于强化治疗的患者。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2011年第1期|共8页
作者
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. [J] . Freyer G, Duret A, Milano G, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第1期

机译：基于伊立替康的一线化疗在转移性结直肠癌中的药物遗传学定制：一项初步研究的结果。
3. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study [J] . Norbert Marschner, Dirk Arnold, Erik Engel, Clinical Epidemiology . 2015,第1期

机译：与基于伊立替康的一线治疗相比，基于奥沙利铂的一线化疗可改善转移性结直肠癌患者的总生存率–前瞻性队列研究结果
4. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort [J] . Rouyer Magali, Smith Denis, Laurent Christophe, Targeted oncology . 2016,第1期

机译：贝伐单抗加伊立替康为基础的化学疗法在现实生活中转移性结直肠癌的一线治疗后继发转移性切除：ETNA研究的结果
5. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
6. Comfort Levels of Gynecology Cancer Patients Receiving Intraperitoneal Chemotherapy: A Pilot Study. [D] . Whyte, Darlene. 2010

机译：接受腹腔化疗的妇科癌症患者的舒适度水平：一项先导研究。
7. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study [O] . Norbert Marschner, Dirk Arnold, Erik Engel, 2015

机译：与基于伊立替康的一线治疗相比基于奥沙利铂的一线化疗可改善转移性结直肠癌患者的总生存率–前瞻性队列研究结果
8. UGT1A1 genotyping for irinotecan-based chemotherapy in the first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia: Report of cases [O] . Yeh Yung-Sung, Wu Ming-Xia, Huang Meng-Lin, 2013

机译：UGT1A1基因型用于基于伊立替康的一线治疗转移性结直肠癌高胆红素血症患者的治疗：病例报告

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

摘要

著录项

相似文献

相关主题

期刊订阅